[go: up one dir, main page]

HK1149563B - 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1h-indole-1-acetic acid ethyl ester intermediate compound - Google Patents

4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1h-indole-1-acetic acid ethyl ester intermediate compound Download PDF

Info

Publication number
HK1149563B
HK1149563B HK11107570.0A HK11107570A HK1149563B HK 1149563 B HK1149563 B HK 1149563B HK 11107570 A HK11107570 A HK 11107570A HK 1149563 B HK1149563 B HK 1149563B
Authority
HK
Hong Kong
Prior art keywords
indole
methyl
acetic acid
thio
chlorophenyl
Prior art date
Application number
HK11107570.0A
Other languages
German (de)
French (fr)
Chinese (zh)
Other versions
HK1149563A1 (en
Inventor
Rukhsana Tasneem Mohammed
Roger Victor Bonnert
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0301569A external-priority patent/SE0301569D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1149563A1 publication Critical patent/HK1149563A1/en
Publication of HK1149563B publication Critical patent/HK1149563B/en

Links

Description

The present invention relates to 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-acetic acid, ethyl ester and its use in the preparation of substituted indoles useful as pharmaceutical compounds for treating respiratory disorders
EPA 1 170 594 discloses methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2, a ligand for orphan receptor CRTh2. US 5,486,525 discloses a series of indoles said to possess PAF antagonist activity. It has now surprisingly been found that certain indole acetic acids are active at the CRTh2 receptor, and as a consequence are expected to be potentially useful for the treatment of various respiratory diseases, including asthma and COPD.
In a first aspect the invention therefore provides a compound 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-acetic acid, ethyl ester.
The compound of the invention may be used in the preparation of a compound of formula: and pharmaceutically acceptable salts and solvates thereof.
The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:
  1. (i) the title and sub-titled compounds of the examples and methods were named using the ACD labs/name program (version 6.0) from Advanced Chemical Development Inc, Canada;
  2. (ii) unless stated otherwise, reverse phase preparative HPLC was conducted using a Symmetry, NovaPak or Ex-Terra reverse phase silica column;
  3. (iii) Flash column chromatography refers to normal phase silica chromatography
  4. (iv) solvents were dried with MgSO4 or Na2SO4
  5. (v) Evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;
  6. (vi) Unless otherwise stated, operations were carried out at ambient temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon or nitrogen;
  7. (vii) yields are given for illustration only and are not necessarily the maximum attainable;
  8. (viii) the structures of the end-products of the formula (1) were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet, quin, quintet;
  9. (ix) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), mass spectrometry (MS), infra-red (IR) or NMR analysis;
  10. (x) mass spectra (MS): generally only ions which indicate the parent mass are reported when given, 1H NMR data is quoted in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard;
  11. (xi) the following abbreviations are used:
    • M.p. = melting point
    • THF = tetrahydrofuran
    • EtOAc = ethyl acetate
    • MCPBA = meta chloroperbenzoic acid
    • DMF = N,N-dimethyl formamide
    • MgSO4 = magnesium sulfate
    • Na2SO4= sodium sulfate
    • NaHCO3 = sodium hydrogen carbonate
Example 1
Preparation of 4-(Acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid i) 3-[(4-chlorophenyl)thio]-2-methyl-4-nitro-1H-indole
To a stirred solution of 3-nitroaniline (8 g) in THF (700 ml) cooled to -78 °C was added tert-butyl hypochlorite (6.3 g) dropwise over 5 minutes. The reaction was allowed to warm to -65 ° C over 20 minutes before 1-[4-chlorophenyl)thio]-2-propanone (11.6 g) was added as a solution in THF (20 ml). After 2 hours triethylamine (8.1 ml) was added and the reaction allowed to warm to room temperature. 2M HCl (aq) was added to the reaction mixture before concentration in vacuo. The residue was slurried in methanol and the solid which precipitated isolated by filtration to give the sub-title compound (5.8 g). 1H NMR (DMSO-d6) δ 12.55 (s, 1H), 7.76 (dd, 1H), 7.63 (dd, 1H), 7.31-7.22 (m, 3H), 6.91 (dd, 2H), 2.47 (s, 3H)
ii) 3-[(4-chlorophenyl)thio]-2-methyl-4-nitro-1H-indole-acetic acid, ethyl ester
To a stirred suspension of sodium hydride, 60% dispersion in mineral oil, (0.85 g) in THF (100 ml) was added the product from part (i) (5.6 g) as a solution in THF (50 ml). After stirring at room temperature for 30 minutes ethyl bromoacetate (2.3 ml) was added dropwise over 10 minutes. After 2 hours the reaction was concentrated in vacuo, the residue dissolved in ethyl acetate, washed with water, brine, dried (MgSO4) and concentrated in vacuo. Recrystallisation from ethanol gave the sub-title compound (5 g). 1H NMR (DMSO-d6) δ 7.97 (dd, 1H), 7.65 (dd, 1H), 7.35 (t, 1H), 7.26 (dt, 2H), 6.92 (dt, 2H), 5.40 (s, 2H), 4.19 (q, 2H), 2.45 (s, 3H), 1.22 (t, 3H).
iii) 4-amino-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-acetic acid, ethyl ester
A suspension of the product from part (ii) (2.25 g) in ethanol (170 ml) was stirred in the presence of 5% Pt/C (0.5 g) under 2 bar pressure of H2. After stirring overnight the catalyst was removed by filtration and the filtrates concentrated in vacuo. Purification by flash column chromatography (14% EtOAc/hexane as eluent) to give the sub-title compound (1.4 g). 1H NMR (DMSO-d6) δ 7.30 (dd, 2H), 7.00 (dt, 2H), 6.85 (t,1H), 6.68 (dd, 1H), 6.23 (dd, 1H), 5.33 (s, 2H), 5.09 (s, 2H), 4.16 (q, 2H), 2.33 (s, 3H), 1.21 (t, 3H).
3-[(4-chlorophenyl)thio]-4-(ethylamino)-2-methyl-1H-indole-1-acetic acid, ethyl ester was also isolated as a by product from the reaction (0.33g).
1H NMR (DMSO-d6) δ 7.32 (dd, 2H), 7.01 (dd, 2H), 6.95 (t, 1H), 6.73 (d, 1H), 6.16 (d, 1H), 5.70 (t, 1H), 5.11 (s, 2H), 4.16 (q, 2H), 3.05 (dt, 2H), 2.34 (s, 3H), 1.21 (t, 3H), 1.02 (t, 3H).
iv) 4-(acetylamino)-3-[(4-chlorophenyl)thiol-2-methyl-1H-indole-acetic acid, ethyl ester
To a solution of the product from part (iii) (0.5 g) in dichloromethane (10 ml) was added triethylamine (0.18 ml) and acetyl chloride (0.1 ml), the reaction was stirred at room temperature for 30 minutes. The mixture was then adsorbed onto silica gel and purified by column chromatography (33% EtOAc/hexane as eluent) to give the sub-title compound (0.52 g). 1H NMR (DMSO-d6) δ 9.51 (s, 1H), 7.46 (d, 1H), 7.34 - 7.27 (m, 3H), 7.11(t, 1H), 6.97 (d, 2H), 5.24 (s, 2H), 4.18 (q, 2H), 2.39 (s, 3H), 1.86 (s, 3H), 1.21 (t, 3H).
v) 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-acetic acid
To a solution of the product from part (iv) (0.31 g) in THF (10 ml) was added a 1M solution of NaOH (aq) (0.75 ml). The reaction was stirred overnight at room temperature. The reaction mixture was concentrated in vacuo and the residue dissolved/suspended in water. The pH was adjusted to 2 using dilute HCl (aq) and the solid which precipitated isolated by filtration. Recrystallisation from acetonitrile gave the title compound (0.16 g). 1H NMR (DMSO-d6) δ 13.21 (s, 1H), 9.51 (s, 1H), 7.46 (d, 1H), 7.33 - 7.27 (m, 3H), 7.11 (t, 1H), 6.98 (d, 2H), 5.12 (s, 2H), 2.39 (s, 3H), 1.85 (s, 3H).
APCI+ [M+H] 389
M.p. dec > 266°C
Reference Examples: Reference Example 5
3-[(2-Chlorophenyl)thio]-2-methyl-5-[(methylsulfonyl)amino]-1H-indole-1-acetic acid i) 2-methyl-5-nitro-1H-indole-1-acetic acid, ethyl ester
2-Methyl-5-nitro-1H-indole (5.3 g) was dissolved in dimethyl formamide (20 ml) and to it added sodium hydride (1.2 g) for the mixture to be stirred for 1 hour. Ethyl bromoacetate (6.8 g) was added all at once and a precipitate started to form. The mixture was quenched with 1 % aqueous acetic acid and the precipitate collected by filtration and washed thoroughly with water, triturated with diethyl ether and dried under vacuum to give pure sub-title product (6.2 g). 1H NMR (DMSO-d6) δ 8.45 (d, 1H), 7.96 (dd,1H), 7.59 (d, 1H), 6.56 (s, 1H), 5.21 (s, 2H), 4.16 (q, 2H), 2.37 (s, 3H), 1.19 (t, 3H). APCI- [M-H] 263
ii) 5-amino-2-methyl-1H-indole-1-acetic acid, ethyl ester
A suspension of 2-methyl-5-nitro-1H- indole-1-acetic acid, ethyl ester (6.2 g) in ethanol (600 ml) in the presence of 10% palladium on charcoal (0.6 g) was stirred under a hydrogen atmosphere at 3 bar for 4 hours. The mixture was filtered through celite and the filtrate evaporated to give the sub-title compound as a pink viscous oil (5.3 g). APCI- [M-H] 233
iii) 2-methyl-5-[(methylsulfonyl)amino]-1H-indole-1-acetic acid, ethyl ester
Methanesulfonyl chloride (1.15 g) was added to a solution of 5-amino-2-methyl-1H-indole-1-acetic acid, ethyl ester (2.3 g) in triethylamine (1.7 ml) and dichloromethane (20 ml) at 0 °C a pink viscous oil for a pink viscous oil for and stirred at 20 °C for 1 hour. Water was added and the mixture extracted with dichloromethane, dried (Na2SO4) and evaporated to give the crude solid. This was purified by chromatography using silica (40:1 dichloromethane/ethyl acetate as eluent) to give the sub-title compound as a pink solid (1.4 g). 1H NMR (DMSO-d6) δ 9.23 (s, 1H), 7.30 (m, 2H), 6.94 (dd, 1H), 6.23(s, 1H), 5.03 (s, 2H), 4.14 (q, 2H), 2.85 (s, 3H), 2.31 (s, 3H), 1.19 (t, 3H). APCI- [M-H] 311
iv) 3-[(2-chlorophenyl)thio]-2-methyl-5-[(methylsulfonyl)amino]-1H-indole-1-acetic acid, ethyl ester
2-methyl-5-[(methylsulfonyl)amino]-1H-indole-1-acetic acid, ethyl ester (0.31 g) and 2-chlorobenzenethiol (0.27 g) were dissolved in dimethyl formamide (3 ml) followed by addition of iodine 0.30 g) for the whole to be stirred at room temperature overnight. The mixture was poured into aqueous sodium thiosulphate (50 ml) and the resultant white precipitate collected by filtration and rinsed with water, dried under vacuum to be recrystallised from ethanol. The crystals were harvested and rinsed with isohexane and dried under vacuum to give the sub-title compound (0.20 g) 1H NMR (DMSO-d6) δ 9.34 (s, 1H), 7.55 (d, 1H), 7.45 (m, H), 7.21 (d, 1H), 7.23-7.06 (m, 3H), 6.44 (m,1H), 5.26 (s, 2H), 4.18 (q, 2H), 2.83 (s, 3H), 2.38 (s, 3H), 1.22 (t,3H). APCI- [M-H] 453/455
v) 3-[(2-chlorophenyl)thio]-2-methyl-4-[(methylsulfonyl)amino]-1H-indole-1-acetic acid
The title compound was prepared by the method of Example 1 part (v) except that recrystallisation was not required. (0.10 g) 1H NMR (DMSO-d6) δ 13.25 (s, 1H), 9.33 (s, 1H), 7.54 (d, 1H), 7.45 (dd, 1H), 7.21 (d, 1H), 7.08 (m, 3H), 6.45 (d, 1H), 5.13 (s, 2H), 2.83 (s, 3H), 2.38 (s, 3H). APCI- [M-H] 425/427 M.p. 212 °C
Reference Example 17
4-(Acetylamino)-3-[(3-chlorophenyl)thiol-2-methyl-1H-indole-1-acetic acid i) 4-(acetylamino)-2-methyl-1H-indole-1-acetic acid, ethyl ester
Thiosalicylic acid was added to a solution of the product from Example 1 part (iv) (474 mg) in trifluoroacetic acid (10 ml) was added thiosalicylic acid (351 mg) and the resulting suspension was heated to 60°C for 4 hours. The mixture was concentrated in vacuo and the residue dissolved in EtOAc and washed with NaHCO3 (aq), brine, dried (MgSO4) and evaporated to give crude material. Purification by column chromatography (50% EtOAc/hexane as eluent) gave the sub-title compound (0.13 g). 1H NMR (DMSO-d6) δ 9.51 (s, 1H), 7.54 (d, 1H), 7.07 (d, 1H), 6.96 (t, 1H), 6.50 (s, 1H), 5.02 (s, 2H), 4.14 (q, 2H), 2.33 (d, 3H), 2.12 (s, 3H), 1.20 (t, 3H).
ii) 4-(acetylamino)-3-[(3-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid
The sub-title compound was prepared by the method of Reference Example 5 part (iv) using the product from part (i) (0.11 g) and 3-chlorobenzenethiol (0.048 g), then purified by preparative hplc (eluent MeCN/NH3 (aq)) to give the title compound (70 mg). 1H NMR (DMSO-d6) δ 9.49 (s, 1H), 7.43 (d, 1H), 7.29 (d, 1H), 7.24 (t, 1H), 7.14 (dd, 1H), 7.08 (t, 1H), 6.97 - 6.95 (m, 2H), 4.96 (s, 2H), 2.38 (s, 3H), 1.86 (s, 3H). APCI- [M-H] 387
Reference Example 18
3-[(4-Chlorophenyl)thio]-4-[[(dimethylamino)sulfonyl]amino]-2-methyl-1H-indole-1-acetic acid i) 3-[(4-chlorophenyl)thio]-4-[[(dimethylamino)sulfonyl]amino]-2-methyl-1H-indole-1-acetic acid, ethyl ester
Triethylamine (55 µl) and dimethylsulfamoyl chloride (43 µl) were added to a solution of the product from Example 1 part (iv) (150 mg) in acetonitrile (5 ml). The mixture was heated at reflux for 24 hours, adsorbed onto silica and purified using column chromatography (33% EtOAc/hexane as eluent) to give the sub-title compound (95 mg). 1H NMR (DMSO-d6) δ 8.80 (s, 1H), 7.35 - 7.29 (m, 3H), 7.13 (t, 1H), 7.07 (dd, 1H), 6.99 (dt, 2H), 5.25 (s, 2H), 4.18 (q, 2H), 2.56 (s, 6H), 2.37 (s, 3H), 1.21 (t, 3H).
ii) 3-[(4-chlorophenyl)thio]-4-[[(dimethylamino)sulfonyl]amino]-2-methyl-1H-indole-1-acetic acid
The title compound was prepared using the method of Example 1 part (v) and the product from part (i). 1H NMR (DMSO-d6) δ 8.79 (s, 1H), 7.31 (m, 2H), 7.14 (dd, 1H), 7.04 - 6.99 (m, 4H), 4.51 (s, 2H), 2.54 (s, 6H), 2.34 (s, 3H). APCI- [M-H] 452
Reference Example 21
4-(Acetylamino)-2-methyl-3-[[4-(methylsulfonyl)phenyl]thiol-1H-indole-1-acetic acid i) 4-(methylsulfonyl)benzenethiol
1-fluoro-4-(methylsulfonyl)benzene and sodium bisulphide (10 g) were heated in NMP (10 ml) at 80°C for 2h. The mixture was poured into water, washed with EtOAc, acidified with concentrated hydrochloric acid and extracted with EtOAc. The organics were washed with water, dried (MgSO4) and evaporated to give the sub-title compound, which was used in the next step without characterisation.
ii) 4-(acetylamino)-2-methyl-3-[[4-(methylsulfonyl)phenyl]thio]-1H-indole-1-acetic acid, ethyl ester.
The sub-title compound was prepared by the method of Reference Example 5 part (iv) using the product from part (i) and the product from Reference Example 17 part (i), and purified by chromatography (50% EtOAc/hexane increasing to 66% EtOAc/hexane as eluent) to give the sub-title compound. 1H NMR (DMSO-d6) δ 9.45 (s, 1H), 7.72 (dt, 2H), 7.38 (d, 1H), 7.32 (d, 1H), 7.16 - 7.11 (m, 3H), 5.27 (s, 2H), 4.19 (q, 2H), 3.14 (s, 3H), 2.38 (s, 3H), 1.82 (s, 3H), 1.22 (t, 3H).
iv) 4-(acetylamino)-2-methyl-3-[[4-(methylsulfonyl)phenyl]thio]-1H-indole-1-acetic acid
The title compound was prepared using the method of Example 1 part (v) and the product from part (ii). 1H NMR (DMSO-d6) δ 9.44 (s, 1H), 7.72 (dd, 2H), 7.38 (d, 1H), 7.31 (d, 1H), 7.17 - 7.10 (m, 3H), 5.14 (s, 2H), 3.14 (s, H), 2.38 (s, 3H), 1.82 (s, 3H). APCI- [M-H] 431
Reference Example 22
4-(Acetylamino)-3-[(2-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid 4-(acetylamino)-3-[(2-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid
The title compound was prepared by the method of Reference Example 5 parts (iv) and using the product from Reference Example 17 part (i) and 2-chlorothiophenol, and purified by column chromatography (33% EtOAc/hexane as eluent). The resulting product was treated as outlined in example 1 part (v) to give the title compound. 1H NMR (DMSO-d6) δ 9.43 (s, 1H), 7.46 (dd, 1H), 7.37 (dd, 2H), 7.14 - 7.05 (m, 3H), 6.42 (dd, 1H), 5.14 (s, 2H), 2.37 (s, 3H), 1.81 (s, 3H) APCI+ [M+H] 389
Reference Example 23
4-(Acetylamino)-2-methyl-3-[[4-(ethylsulfonyl)phenyl]thio]-1H-indole-1-acetic acid i) 4-(acetylamino)-2-methyl-3-[[4-(ethylsulfonyl)phenyl]thio]-1H-indole-1-acetic acid
The title compound was prepared by the method of Reference Example 5 part (iv) using the product from Reference Example 17 part (i) and 4-(ethylsulfonyl)benzenethiol. The product was purified by preparative hplc (eluent MeCN/NH3 (aq)). 1H NMR (DMSO-d6) δ 9.41 (s, 1H), 7.66 (d, 2H), 7.30 (d, 2H), 7.17 (d, 2H), 7.08 (t, 1H), 4.85 (s, 2H), 3.20 (q, 2H), 2.37 (s, 3H), 1.78 (s, 3H), 1.05 (t, 3H). APCI- [M-H] 445

Claims (1)

  1. The compound 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indoleacetic acid, ethyl ester.
HK11107570.0A 2003-05-27 2009-06-30 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1h-indole-1-acetic acid ethyl ester intermediate compound HK1149563B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0301569A SE0301569D0 (en) 2003-05-27 2003-05-27 Novel compounds
SE0301569 2003-05-27
SE0302305 2003-08-27
SE0302305A SE0302305D0 (en) 2003-05-27 2003-08-27 Novel Compounds
HK09105852.7A HK1126773B (en) 2003-05-27 2009-06-30 Use of 3-phenylthio-1h-indole-1-acetic acid derivatives as modulators of crth2 receptor activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK09105852.7A Addition HK1126773B (en) 2003-05-27 2009-06-30 Use of 3-phenylthio-1h-indole-1-acetic acid derivatives as modulators of crth2 receptor activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK09105852.7A Division HK1126773B (en) 2003-05-27 2009-06-30 Use of 3-phenylthio-1h-indole-1-acetic acid derivatives as modulators of crth2 receptor activity

Publications (2)

Publication Number Publication Date
HK1149563A1 HK1149563A1 (en) 2011-10-07
HK1149563B true HK1149563B (en) 2012-12-14

Family

ID=

Similar Documents

Publication Publication Date Title
EP2281815B1 (en) 4-(Acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid ethyl ester intermediate compound
KR890000184B1 (en) Method for preparing novel 6-substituted-s-triazolo [3,4-a] phthalazine derivatives
US5430148A (en) Antiproliferative quinazolines
EP0950047B1 (en) Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them
EP1902034B1 (en) Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
MXPA01010915A (en) 3alpha-HYDROXY-3beta METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY.
EP0362695A1 (en) Pyrrolocarbazole derivatives, processes for their preparation and their use as medicaments
CZ20014496A3 (en) Indole derivatives and their use for treating osteoporosis
JPH051267B2 (en)
JPH04134077A (en) Isoxazole compounds
JPS61155358A (en) Diallylbutyric acid derivative and production thereof
EP0104522A2 (en) New pyrazolo(3,4-b)pyridine derivatives and process for producing them
EP0370236A1 (en) Indolocarbazole derivatives, processes for their preparation and their use as medicaments
TWI259085B (en) Piperazine derivatives having SST1 antagonistic activity
IE63209B1 (en) Hetera-aliphatic carboxamides
JPH05194359A (en) New urea derivative, and its preparation and therapeutical use
EP0009655B1 (en) 6-amino substituted n-pyrrolyl-3-pyridazine amines, their preparation, and pharmaceutically antihypertensive compositions containing them
EP0008249A2 (en) Fluorene and fluoranthene derivatives, process for their preparation and their therapeutic application
HUT71132A (en) Bis-aryl-carbinol derivatives, pharmaceutical compositions containing them and process for producing
FR2601011A1 (en) NEW AGONISTIC TRICYCLIC DERIVATIVES OF CHOLINERGIC RECEPTORS AND MEDICAMENTS CONTAINING SAME
JPH0673012A (en) 4-iminoquinoline, its preparation and its use
NO164899B (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE IMIDAZOLYLINDOL COMPOUNDS.
KR20190015305A (en) A pharmaceutically acceptable salt as an extrinsic aqueous potassium channel inhibitor
HK1149563B (en) 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1h-indole-1-acetic acid ethyl ester intermediate compound
US6069257A (en) Process for the production of tetrazolylbenzopyrans